Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin

Kowa Research Institute, Inc.28 enrolled

Overview

This is a Phase 4, single-center, open-label, fixed-sequence, multiple-dose, 2-way drug-drug interaction study.

Each subject will qualify for entry into the study not more than 30 days prior to admission into the clinical unit. Subjects will check into the clinical unit on Day -1 for baseline assessments. During the treatment period, each subject will receive a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15. Subjects will fast overnight for at least 8 hours before dosing and will remain fasted until 4 hours after dosing on the morning of Days 5, 10, and 15.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Pitavastatin (NK-104)DRUG

pitavastatin (NK-104) 4 mg once daily (QD)

Diltiazem (Cardizem LA) 240 mg QDDRUG

Diltiazem (Cardizem LA) 240 mg QD

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy adult male or female volunteer aged 18 to 45 years, inclusive. * Subject has a body mass index of 18 to 30 kg/m2, inclusive. * Subject has normal hematology, serum chemistry, and urinalysis test results. * Subject is able and willing to abstain from alcohol, grapefruit-containing foods or beverages, caffeine, or caffeine-containing products, St John's wort, and herbal supplements for 4 days before Day 1 and until after completion of this study. * Subject is a nonsmoker or has quit smoking at least 6 months before the first dose of study drug and until after study completion. Exclusion Criteria: * Subject has had any surgery of the gastrointestinal tract likely to affect drug absorption, distribution, metabolism, or excretion. * Subject has had a previous allergy or intolerance to treatment with pitavastatin, diltiazem, or any drugs in these classes. * Subject has a history of drug or alcohol abuse. * Subject has had a clinically significant illness within 4 weeks before the first dose of study drug.

Locations (1)

Unnamed facility

Austin, Texas, United States

Outcomes

Primary Outcomes

NK-104 AUC

Time frame: 15 Days

Secondary Outcomes

Number of Participants With at Least One Adverse Event.

Time frame: 24 Days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.